West Pharmaceutical Services (NYSE:WST) Sets New 12-Month High After Better-Than-Expected Earnings

West Pharmaceutical Services, Inc. (NYSE:WST) hit a new 52-week high during mid-day trading on Thursday following a stronger than expected earnings report. The stock traded as high as $386.00 and last traded at $362.5410, with a volume of 169878 shares trading hands. The stock had previously closed at $358.41.

The medical instruments supplier reported $2.37 EPS for the quarter, beating the consensus estimate of $2.08 by $0.29. The firm had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The company’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS.

West Pharmaceutical Services Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th will be given a dividend of $0.22 per share. The ex-dividend date of this dividend is Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio is presently 11.76%.

Key Stories Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: West Pharmaceutical beat Q2 expectations, reporting adjusted EPS of $2.37 versus $2.08 expected and revenue of $872.3 million versus $840.0 million expected, showing solid demand across its business. West Reports Second-Quarter 2026 Results
• Positive Sentiment: The company raised full-year 2026 guidance, now expecting EPS of $8.85 to $9.05 and revenue of $3.3 billion to $3.4 billion, both above prior expectations. West Pharmaceutical raises annual profit forecast on strong demand for injectable drug components
• Positive Sentiment: Management pointed to strong demand for high-value products, including components tied to GLP-1, diabetes, obesity, and biologics drugs, which is helping drive growth and improve investor sentiment. West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum
• Neutral Sentiment: The company also issued Q3 guidance slightly above analyst estimates, reinforcing confidence in near-term momentum. West Pharmaceutical Raises 2026 Guidance After Strong Quarter

Wall Street Analyst Weigh In

WST has been the topic of several research analyst reports. Wolfe Research began coverage on West Pharmaceutical Services in a research note on Monday, June 1st. They set an “outperform” rating and a $375.00 target price on the stock. Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $310.00 to $400.00 in a report on Tuesday, June 9th. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, April 27th. Stephens restated an “overweight” rating and issued a $360.00 price objective on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Finally, Citigroup reaffirmed a “buy” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, West Pharmaceutical Services has an average rating of “Buy” and an average target price of $363.17.

Insider Activity at West Pharmaceutical Services

In other news, VP Annette F. Favorite sold 2,817 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the transaction, the vice president owned 16,828 shares in the company, valued at $5,135,905.60. This trade represents a 14.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the sale, the chief accounting officer owned 1,523 shares in the company, valued at $457,920.41. This represents a 37.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. State Street Corp grew its holdings in West Pharmaceutical Services by 2.1% in the second quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier’s stock worth $715,884,000 after purchasing an additional 68,330 shares during the period. Artisan Partners Limited Partnership lifted its holdings in shares of West Pharmaceutical Services by 2.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 2,850,401 shares of the medical instruments supplier’s stock valued at $784,259,000 after purchasing an additional 79,481 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of West Pharmaceutical Services by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 1,869,086 shares of the medical instruments supplier’s stock worth $512,250,000 after purchasing an additional 11,962 shares in the last quarter. Generation Investment Management LLP boosted its position in shares of West Pharmaceutical Services by 60.0% in the 4th quarter. Generation Investment Management LLP now owns 1,561,869 shares of the medical instruments supplier’s stock worth $429,733,000 after purchasing an additional 585,855 shares in the last quarter. Finally, Morgan Stanley grew its stake in shares of West Pharmaceutical Services by 3.6% in the 4th quarter. Morgan Stanley now owns 1,531,858 shares of the medical instruments supplier’s stock worth $421,476,000 after buying an additional 53,229 shares during the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Price Performance

The company has a current ratio of 2.71, a quick ratio of 2.04 and a debt-to-equity ratio of 0.07. The company has a market cap of $25.10 billion, a PE ratio of 47.49, a P/E/G ratio of 2.90 and a beta of 1.16. The firm has a 50 day moving average of $336.51 and a two-hundred day moving average of $287.14.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.